Using Whole-Genome Sequencing To Study Early-Onset Parkinson’s Disease (CSRWire)

Using Whole-Genome Sequencing To Study Early-Onset Parkinson’s Disease

JENNIFER JOHNSTON, CO-FOUNDER AND CEO OF NYSNOBIO | PHOTO: DAVID STEELE

The Norwegian term for virgin snow, “nysnø”, seemed the appropriate inspiration to name Jennifer Johnston’s company, NysnoBio, as it underscores the pioneering work NysnoBio is doing to tap the potential of Parkin, the protein most often linked to young onset genetic Parkinson’s disease.

“NysnoBio is focused on the most common cause of early-onset Parkinson’s disease,” Johnston says. “If you are missing this gene, it is 100 percent certain that you will get Parkinson’s disease before the age of 45.” Her team is seeking a therapy to replace the gene in people who are missing it, to arrest progression of the disease in patients.

Learn more about Using Whole-Genome Sequencing To Study Early-Onset Parkinson’s Disease